Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT)
Status:
Not yet recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
phase II controlled randomized study comparing atezolizumab as single agent to the
combination of atezolizumab and bevacizumab in patients with chemonaive metastatic NSCLC with
PD-L1 expression. All NSCLC patients with tumor tissue available for biomarker assessment and
candidate for first-line therapy are considered eligible for the study. After evaluation of
all inclusion and exclusion criteria and after informed consent signature all eligible
patients will be randomized to atezolizumab (Arm A) or to the combination of atezolizumab and
bevacizumab (Arm B). Disease assessment will be performed every 6 weeks.